Epitope Diagnostics Launches the Second Generation Immunoassay Kits Exclusively for the Quantitative Measurement of Antibody Drug Conjugate (ADC) Levels
San Diego, CA, October 12, 2013 --(PR.com
)-- Epitope Diagnostics, Inc. is proud to introduce second generation ADC kits that measure both humanized monoclonal antibody-based ADC and mouse monoclonal antibody-based ADC. This new model of EIA kits has been developed to best fit PK studies and broadly apply to samples from almost all species (including mouse, rat, primate, human, etc.).
Measurement of circulating specific cytotoxic ADCs are extremely important for pre-clinical and clinical studies Based on the specific antibodies against DM1, MMAE, MMAF, Epitope Diagnostics has developed three enzyme immunoassay (EIA) kits measuring DM1-ADC, MMAE-ADC, and MMAF-ADC (respective antibody conjugates). These EIA kits were developed by coating anti-DM1/MMAE/MMAF-specific antibodies to microtiter plates. The advantage of using this test method is that there is no assay interference, even from a high concentration of mouse immunoglobulin in test specimens. Incredibly, the analytical sensitivity (LLOD) of these second generation ADC kits is higher (0.0012 μg/mL) than the first generation kits. The DAR of ADC conjugate has less of an impact of the test results.
Much like the first generation ADC EIA kits, these newly developed kits feature a total incubation period of less than 3 hours. The standard curve spans from 0.030 μg/mL to 20 μg/mL. The assay procedure is very simple to perform with just a one-step plate wash.
"We're very excited to offer these second generation quantitative ADC test in ELISA format. These test kits will be extremely useful in studies related to ADC metabolism or pharmacokinetics, particularly in the mouse model, in which there is no need for any sample dilution," says Epitope Diagnostics' President, Ping Gao. "Our effort to improve the drug development and pharmaceutical community is very gratifying. We will continually strive to develop innovative tests for the benefit of the ADC community."
The second generation EDI™ DM1 ADC EIA Kit, EDI™ MMAE ADC EIA Kit, and the EDI™ MMAF ADC EIA Kit are available now. Additionally, high affinity and specific antibodies to DM1, MMAE and MMAF are also available. Epitope Diagnostics is currently interested in collaborating with pharmaceutical companies to develop and manufacture customized ADC immunoassays and antibodies. For more information, contact the Epitope Diagnostics, Inc. customer service department at email@example.com or by telephone: +1 (858) 693-7877
1) DM1 ADC EIA Kit (KTR756)
2) MMAE ADC EIA Kit (KTR757)
3) MMAF ADC EIA Kit (KTR758)
The Next Advancements in Cancer Drug Development: Antibody-Drug Conjugates - Onco'Zine - The International Cancer Network, June 14, 2012 
Dimond (9 Mar 2010). "Antibody-Drug Conjugates Stage a Comeback"
Doronina SO et al. Nat Biotechnol. 2003;21(7):778-784
Alley SC et al. Curr Opin Chem Biol. 2010;14(4):529-537
Hamblett KJ et al. Clin Cancer Res. 2004;10(20):7063-7070
Antibody Drug Conjugates: A Marriage of Biologics and Small Molecules - Pharmaceutical Technology. Pharmtech.findpharma.com.